Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Carisma Therapeutics Inc.

    NASDAQ: CARM · Real-Time Price · USD
    0.45
    -0.10 (-17.91%)
    At close: Jun 13, 2025, 3:59 PM

    Carisma Therapeutics Statistics

    Share Statistics

    Carisma Therapeutics has 41.79M shares outstanding. The number of shares has increased by 0.5% in one year.

    Shares Outstanding

    n/a
    		 41.79M

    Shares Change (YoY)

    n/a
    		 0.5%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 11.51%

    Shares Floating

    n/a
    		 21.12M

    Failed to Deliver (FTD) Shares

    n/a
    		 3

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 694.37K, so 1.66% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 694.37K

    Short % of Shares Out

    n/a
    		 1.66%

    Short % of Float

    n/a
    		 1.89%

    Short Ratio (days to cover)

    n/a
    		 1.04

    Valuation Ratios

    The PE ratio is -0.29 and the forward PE ratio is -0.9. Carisma Therapeutics's PEG ratio is 0.01.

    PE Ratio

    n/a
    		 -0.29

    Forward PE

    n/a
    		 -0.9

    PS Ratio

    n/a
    		 0.88

    Forward PS

    n/a
    		 0.3

    PB Ratio

    n/a
    		 -0.62

    P/FCF Ratio

    n/a
    		 -0.29

    PEG Ratio

    n/a
    		 0.01
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Carisma Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 1.48, with a Debt / Equity ratio of -0.09.

    Current Ratio

    n/a
    		 1.48

    Quick Ratio

    n/a
    		 1.48

    Debt / Equity

    n/a
    		 -0.09

    Debt / EBITDA

    n/a
    		 -0.04

    Debt / FCF

    n/a
    		 -0.04

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $426,782.61

    Profits Per Employee

    n/a
    		 $-1,314,717.39

    Employee Count

    n/a
    		 46

    Asset Turnover

    n/a
    		 0.64

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -52.99% in the last 52 weeks. The beta is 2.79, so Carisma Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.79

    52-Week Price Change

    n/a
    		 -52.99%

    50-Day Moving Average

    n/a
    		 0.23

    200-Day Moving Average

    n/a
    		 0.58

    Relative Strength Index (RSI)

    n/a
    		 59.12

    Average Volume (20 Days)

    n/a
    		 13,102,022

    Income Statement

    In the last 12 months, Carisma Therapeutics had revenue of 19.63M and earned -60.48M in profits. Earnings per share was -1.46.

    Revenue

    n/a
    		 19.63M

    Gross Profit

    n/a
    		 19.63M

    Operating Income

    n/a
    		 -62.18M

    Net Income

    n/a
    		 -60.48M

    EBITDA

    n/a
    		 -57.12M

    EBIT

    n/a
    		 -62.18M

    Earnings Per Share (EPS)

    n/a
    		 -1.46
    Full Income Statement

    Balance Sheet

    The company has 17.91M in cash and 2.48M in debt, giving a net cash position of 15.43M.

    Cash & Cash Equivalents

    n/a
    		 17.91M

    Total Debt

    n/a
    		 2.48M

    Net Cash

    n/a
    		 15.43M

    Retained Earnings

    n/a
    		 -305.58M

    Total Assets

    n/a
    		 15.95M

    Working Capital

    n/a
    		 3.51M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -59.92M and capital expenditures -123K, giving a free cash flow of -60.04M.

    Operating Cash Flow

    n/a
    		 -59.92M

    Capital Expenditures

    n/a
    		 -123K

    Free Cash Flow

    n/a
    		 -60.04M

    FCF Per Share

    n/a
    		 -1.45
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -316.72% and -308.05%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -316.72%

    Pretax Margin

    n/a
    		 -308.05%

    Profit Margin

    n/a
    		 -308.05%

    EBITDA Margin

    n/a
    		 -290.97%

    EBIT Margin

    n/a
    		 -316.72%

    FCF Margin

    n/a
    		 -305.83%

    Dividends & Yields

    CARM does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for CARM is $1, which is 81.8% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $1

    Price Target Difference

    n/a
    		 81.8%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 6
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Mar 8, 2023. It was a backward split with a ratio of 1:20.

    Last Split Date

    n/a
    		 Mar 8, 2023

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:20

    Scores

    Altman Z-Score

    n/a
    		 -35.04

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist